What are the opening hours?

Monday 9am - 5pm Tuesday 9am - 5pm Wednesday 9am - 5pm Thursday 9am - 5pm Friday 9am - 5pm

Australasian Leukaemia & Lymphoma Group - ALLG

Home
Australia
Melbourne, VIC
Australasian Leukaemia & Lymphoma Group - ALLG

For patients, this means an improved chance of cure, and better quality of life.

Since 1973 the ALLG has been pioneering life-changing blood cancer clinical trials, delivering innovative treatment options that transform the lives of those with blood cancer. The Australasian Leukaemia & Lymphoma Group (ALLG) is the only not-for-profit, collaborative clinical research group in Australia and New Zealand dedicated to finding new ways to treat blood cancers such as leukaemia, lymphoma, myeloma and myelodysplastic syndromes. The ALLG membership includes more than 1,000 doctors, nurses, scientists and support staff across Australia and New Zealand, all of whom are looking for ways to better treat blood cancers through clinical research. By conducting national and international collaborative clinical trials at sites across Australia and New Zealand, ALLG researchers are helping to make new and more effective treatments available to people suffering from blood cancers.

24/09/2025

On , we celebrate the power of clinical trial research in advancing new and better treatments that increase survival and enhance quality of life for people with blood cancer worldwide.

Patients like Ania, a trial participant on our AMLM26 INTERCEPT trial, who was diagnosed with the aggressive Acute Myeloid Leukaemia and given only four weeks to live. Because of ALLG's AMLM26 clinical trial, Ania's life was prolonged for an incredible 17 months, giving her precious time with family. Her daughter Belinda shares her mum's Ania's experience - https://tinyurl.com/2w5cy9bx.

"There are incredible results coming out of early phase trials all over the world, and the ALLG should be so incredibly proud of the research they are doing, targeting Leukemias, Lymphomas and Myelomas. What the ALLG did for my Mum was give her the hope she was looking for, knowing that her body will have contributed to science and the future of AML research – and this can only be of benefit to other people in future." - Belinda, Ania's daughter.

Every approved treatment today started with a clinical trial. Clinical trial research is the vital link between a discovery in the laboratory reaching patients at the bedside – and changing countless lives.

This , support research, save lives - visit allg.org.au.

23/09/2025

What a month it's been! So many cuppas drunk and countless treats baked and shared! Our fantastic community showed up in force and looked great doing it! Thank you to everyone who went and raised critical funds for blood cancer clinical trial throughout September. Good news - if you were not able to go in September, there's still time. Pick a date that suits you, gather your community and follow the link to get started - https://www.allg.org.au/support-us/fundraise-for-us/.

22/09/2025

Today is (CML) Day. ALLG researchers have been world-leaders in the development of new and better treatments and diagnostic techniques for CML over the past 20 years, to the benefit of patients.

Patients like Brian, who received the news of his CML diagnosis with shock, knowing that “leukaemia was not something that could be excised from the body with a surgeon’s knife.” Brian’s doctor suggested that he take part in the ALLG CML9 TIDELL II clinical trial. He was treated with a tyrosine kinase inhibitor (TKI) therapy, coupled with frequent blood tests and molecular monitoring.

“I was extremely fortunate in that I responded exceedingly well to the drug prescribed to me,” he said. “Within a matter of weeks, I obtained a ‘major molecular response’. This is one of the prime objectives of a CML patient and an indicator of a superior longer-term outcome, though certainly no guarantee.” Brian was eventually able to move onto a new clinical trial and treatment-free remission.

Brian’s positive outcome is a result of ALLG’s leading CML research. Our ALLG researchers are committed to delivering innovative clinical trials that transform blood cancer treatments and provide hope to patients like Brian. For more information on ALLG’s leading blood cancer research, visit allg.org.au.

20/09/2025

Today is . ALL or Acute Lymphoblastic Leukaemia is a blood cancer that appears suddenly and grows quickly.

In the last 20 years, treatments for ALL in children and adults have seen significant progress, but adolescents and young adults (AYA) patients still face lower survival rates and fewer treatment options.

ALLG’s ALL09 SUBLIME clinical trial addressed this unmet need, using a targeted immunotherapy called blinatumomab in conjunction with chemotherapy to improve overall survival and reduce the risk of cancer relapse in AYA patients.

Bianca was a participant in the ALL09 clinical trial, after she was diagnosed with ALL after a routine blood test for an unrelated health issue. Bianca said, “The news came as a big shock … I had to start my treatment within less than three days of being diagnosed … I did have the option of doing conventional treatment, but I read through the clinical trial documents, and it seemed like a better option for me.”

Bianca’s treatment with the new ALL09 therapy was successful and she was able to get back to her normal life. She said, “Bianca said, “Research is important to continue improving medicines and giving the overall best care to patients.”

Results of the successful ALL09 trial showed that the new treatment had higher rates of remission and fewer toxic side effects for patients with ALL.

The ALL09 SUBLIME trial results continue to influence treatment practice across Australasia, with the research abstract accepted for presentation at the leading haematology conference, Blood, in Perth in October 2025..

Support Research, Save Lives – be part of the breakthrough this Blood Cancer Awareness Month and donate to support ALLG’s world-leading research – allg.org.au.

19/09/2025

ALLG's member doctors witness firsthand how clinical trials offer more than just new blood cancer treatments to patients - they offer hope at the most difficult of times.

ALLG's independent, doctor-led clinical trials provide access to potentially better treatments that address the most pressing needs of patients with blood cancers such as leukaemia, lymphoma and myeloma. Through ALLG's research and clinical trials, blood cancer patients are achieving better survival outcomes, staying in remission longer and experiencing better quality of life through less toxic, more targeted treatments. Our researchers are changing the way blood cancers are treated, both here in Australia and globally.

Every approved cancer treatment in use today started with a clinical trial. This Blood Cancer Awareness Month, support research that saves lives and creates much needed treatment breakthroughs. Donate to ALLG today. https://www.allg.org.au/make-a-donation/.

17/09/2025

Today is Safety Day. ALLG is committed to ensuring that patient safety is the top priority in all our research, through our Safety Data and Monitoring Committee (SDMC). The SDMC is an independent panel of experts encompassing clinicians, statisticians, ethicists and consumer representatives. They play a crucial role in reviewing trial designs and the conduct of ALLG clinical trials to ensure that the safety of all trial participants.

Patient-centred research is vital to conducting high-quality clinical trial research. ALLG has a patient-centric focus at every stage - from early trial design, to trial conduct, to the reporting of trial outcomes. Our Consumer Representative Panel and our Safety and Data Monitoring Committee play a vital role in this work.

By placing a strong emphasis on measures important to patients, such as quality of life, we are continuously improving how ALLG trials are designed and delivered as we aim for Better treatments…Better lives. Read more - https://www.allg.org.au/clinical-trials-patient-first-focus/.

15/09/2025

Today on , Emma's story is a powerful reminder of the vital role clinical trial research plays in advancing new, better cancer treatments and providing hope. Emma was only 38 when she was diagnosed with an aggressive form of Hodgkin Lymphoma, with doctors finding an 11cm tumour wrapped around her aorta and oesophagus.

Emma’s doctor recommended she take part in the ALLG HD10 clinical trial, providing accessing to a new treatment option that required fewer chemotherapy cycles, resulted in less side effects and preserved fertility. Emma’s trial experience was positive and she is now in remission. You can read more about Emma’s ALLG lymphoma trial experience here: https://tinyurl.com/8tucvx63.

ALLG is committed to designing and delivering clinical trials across all areas of unmet need for blood cancers. Our researchers are at the forefront of clinical trial research, with over 75 active trials across leukaemia, lymphoma & myeloma.

Support Research, Save Lives – Be Part of the Breakthrough and support ALLG’s blood cancer research today - https://www.allg.org.au/support-us/.

11/09/2025

On Myeloproliferative Neoplasms (MPN) Awareness Day, we're proud to highlight an exciting new initiative between our MPN research leaders and Stem Cell Transplantation Working Party. This effort focuses on advancing and better understanding care for patients with Myeloproliferative Neoplasms, particularly those with difficult-to-treat forms such as myelofibrosis.

As part of this initiative, ALLG has launched a new dedicated discussion group led by Professor David Curtis from Monash University/Alfred Hospital. The group is focused on reviewing current therapies and the best treatment options available, and identifying gaps in difficult-to-treat MPN cases, driving future directions in research and best practice care.

By addressing the complexities of MPNs and subtypes such as myelofibrosis, we can ensure that patient needs remain central to innovation and progress in treatments for MPNs.

Support Research, Save Lives. For more information about ALLG’s research, visit allg.org.au.

10/09/2025

ALLG conducts world-leading, innovative blood cancer clinical trials that have global impact - and our BM12 CAST trial is a powerful example.

The BM12 CAST trial assessed a new treatment combination for stem cell transplant that tripled the chance of a patient being alive, in remission and free of the irreversible and debilitating Graft Versus Host Disease (GVHD).

Clinical trials are vital to bring new, better treatments to people with blood cancer and drive progress worldwide. Watch the video from BM12 Chief Investigator Professor David Curtis to learn about the impact of BM12 for people undergoing stem cell transplant for blood cancers. To find out more about ALLG’s research and read more inspiring stories, visit https://www.allg.org.au/about-us/survivor-stories/. Support Research, Save Lives.

08/09/2025

When Claudio was diagnosed with the blood cancer Multiple Myeloma, his world changed overnight. His doctor suggested he take part in an ALLG clinical trial, providing access to a potentially better treatment and giving him something so important - hope.

Through the ALLG trial, Claudio was able to receive the new treatment. He had a positive treatment experience, with no side effects and his myeloma in remission. Watch the video as Claudio shares his personal journey.

Clinical trials are the vital link between a discovery in the lab reaching patients at the bedside. If you or a loved one is facing a blood cancer diagnosis, talk to your treating doctor about what clinical trials may be right for you.

To find out more about ALLG’s clinical trial research, or to support our work, visit allg.org.au.

05/09/2025

A world without blood cancer could be the legacy you leave behind.

During Blood Cancer Awareness Month, ALLG is getting behind the 'Include A Charity Week 2025' campaign to encourage our wonderful community to consider leaving a gift in your will in support of ALLG’s lifesaving blood cancer research. By leaving a gift in your will for ALLG, you are ensuring our brilliant doctor researchers across Australia and New Zealand can bring new treatments and hope to those who need it most - the nearly 20,000 Australians diagnosed every year with a blood cancer such as leukaemia, lymphoma and myeloma.

Your gift ensures ALLG’s researchers can access the vital tools they need to power innovative research into better ways to prevent, treat and cure blood cancer. Your legacy will support significant breakthroughs in blood cancer research that ultimately benefiting people with blood cancer now and in the future.

To find out about leaving a gift in your will for blood cancer research, visit https://tinyurl.com/3x6pwmpb. You can also access our free online Wills platform to support you in the process.

04/09/2025

ALLG's AMLM26 INTERCEPT trial is a world-first trial for acute myeloid leukaemia (AML). This molecularly targeted, multi-arm study is currently exploring 6 new treatments simultaneously, aimed at patients with evidence of measurable residual disease (MRD) and with the objective to prevent AML from relapsing via a preemptive interventional strategy.

AMLM26 has been designed as a platform trial, which enables the study to evolve through addition of new treatment arms over time and as new therapies arise. This design recognises the evolving biology of AML, allowing the patient to rotate to another treatment option if considered beneficial, with the goal of keeping the patient in remission longer and preventing relapse.

This study represents how AML is likely to be managed in the future - with a focus on earlier, personalised and adaptive therapy. A major advantage of this approach is the reduced toxicity associated with earlier intervention, prior to the patient deteriorating clinically.

The AMLM26 INTERCEPT trial received approval by the FDA and is open in the United States in collaboration with investigators at MD Anderson Cancer Centre in Texas.

This Blood Cancer Awareness Month, be part of the breakthrough and partner with ALLG support our world-first, breakthrough research that accelerates blood cancer treatments and saves lives - allg.org.au.

Address

Ground Floor, 35 Elizabeth Street
Melbourne, VIC
3121

Opening Hours

Monday	9am - 5pm
Tuesday	9am - 5pm
Wednesday	9am - 5pm
Thursday	9am - 5pm
Friday	9am - 5pm

Website

https://www.allg.org.au/support-us/make-a-donation/

Alerts

Be the first to know and let us send you an email when Australasian Leukaemia & Lymphoma Group - ALLG posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Australasian Leukaemia & Lymphoma Group - ALLG:

Shortcuts

Featured

Hands-On Laser Cosmetic Clinic
347 Somerville Road, Yarraville

Want your practice to be the top-listed Clinic in Melbourne?

Our Story

The Australasian Leukaemia & Lymphoma Group (ALLG) is the only not-for-profit, investigator run clinical research group in Australia and New Zealand dedicated to finding new ways to treat blood cancers such as leukaemia, lymphoma, myeloma and myelodysplastic syndromes. The ALLG membership includes more than 750 doctors, nurses, scientists and professional staff across Australia and New Zealand, all of whom are looking for ways to better treat blood cancers through clinical research. By conducting national and international collaborative clinical trials at sites across Australia and New Zealand, ALLG researchers are helping to make new and more effective treatments available to people suffering from blood cancers. For patients, this means an improved chance of cure, and better quality of life.